Recommended content

Cannabis drug trial for brain tumours, backed by Olympian Tom Daley, secures research funding

Following a phase I trial that demonstrated promising results in treating the most aggressive form of brain cancer with a cannabis-based drug, phase II trials are set to begin in March 2022.

Story continues below

This advertisement has not loaded yet, but your article continues below.

The trial will build on previous research in treating recurrent glioblastoma with chemotherapy and Sativex, an oral spray containing 1:1 tetrahydrocannabinol (THC) and cannabidiol (CBD).

Funding for the University of Leeds-led trial was secured by The Brain Tumour Charity, a U.K.-based organization.

Earlier this year, the charity announced it was seeking to raise £450,000 ($785,000) needed to fund the trial over a three-year period. Within three months of that announcement, the fundraising

Read full article on The Growth Op

Follow us on Instagram or join our Telegram channel

Be first to rate

The Growth Op

More news